Treatment of vancomycin-resistant enterococci, with a focus on quinupristin-dalfopristin.

Published

Journal Article (Review)

Enterococci are the second most common cause of hospital-acquired infections, and drug resistance among these organisms is a growing problem. Vancomycin-resistant enterococci (VRE) now account for 7.9% of the nosocomial enterococcal infections. There is no standard therapy for VRE. Although some agents have shown in vitro activity alone or in combination, including ciprofloxacin, doxycycline, novobiocin, teicoplanin, chloramphenicol, and rifampin, treatment options are limited to combinations of drugs with marginal efficacy against the pathogens. Quinupristin-dalfopristin is a new investigational agent with activity against gram-positive cocci, including VRE.

Full Text

Duke Authors

Cited Authors

  • Fuller, RE; Drew, RH; Perfect, JR

Published Date

  • July 1996

Published In

Volume / Issue

  • 16 / 4

Start / End Page

  • 584 - 592

PubMed ID

  • 8840364

Pubmed Central ID

  • 8840364

International Standard Serial Number (ISSN)

  • 0277-0008

Language

  • eng

Conference Location

  • United States